Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

This study has been completed.

First Received on July 3, 2001. Last Updated on January 20, 2009 History of Changes

Sponsor:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018642

Purpose

The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.

Condition	Intervention
Schizophrenia Schizoaffective Disorder	Drug: quetiapine Drug: haloperidol decanoate

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Primary Purpose: Treatment
Official Title:	Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Haloperidol Haloperidol decanoate Haloperidol lactate Quetiapine Quetiapine fumarate

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	April 1997
Estimated Study Completion Date:	March 2002

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV
Between the ages 18-60.
A candidate for maintenance antipsychotic therapy. This means that patients will have had at least two documented episodes of acute schizophrenic illness or at least two years of continuing psychotic symptoms.

Exclusion Criteria

Organic brain disease.
Mental Retardation
Chronic medical illness which would make antipsychotic medication inappropriate.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018642

Locations

United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073

Sponsors and Collaborators

Department of Veterans Affairs

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00018642 History of Changes
Other Study ID Numbers:	MHBS-042-96F
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

quetiapine
haloperidol decanoate

Additional relevant MeSH terms:

Psychotic Disorders
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Haloperidol decanoate
Haloperidol
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions

Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents

ClinicalTrials.gov processed this record on February 09, 2012